Antitumor antibodies, proteins, and uses thereof

Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S330000, C530S387700, C530S388800, C530S391300, C530S391700

Reexamination Certificate

active

07902339

ABSTRACT:
Antibodies that bind to a 40 kDa protein which is expressed on tumors, but is not expressed on normal adult hemopoietic cells are disclosed. Also disclosed are methods for production and the use of such antibodies.

REFERENCES:
patent: 5576423 (1996-11-01), Aversa et al.
patent: 5756096 (1998-05-01), Newman
patent: 5817513 (1998-10-01), Lopez et al.
patent: 5830470 (1998-11-01), Nakamura
patent: 6042828 (2000-03-01), Nakamura et al.
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6156321 (2000-12-01), Thorpe et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 2006/0275307 (2006-12-01), Fanger et al.
patent: 2007/0031423 (2007-02-01), Fanger et al.
patent: 0369425 (1990-05-01), None
patent: 0882794 (1998-12-01), None
patent: WO-01/07481 (2001-02-01), None
patent: WO-01/91793 (2001-12-01), None
Boyer et al. (Int. J. Cancer. 1999; 82: 525-531).
Press et al. (J. Immunol. Dec. 15, 1988; 141 (12): 4410-4417).
Riemer et al. (Mol. Immunol. 2005; 42: 1121-1124).
Pettersen et al. (J. Immunol. Jun. 15, 1999; 162 (12): 7031-7040.
Bernard et al. (Human Immunol. 1986; 17: 388-405).
Lewis et al. (Cancer Immunol. Immunother. Sep. 1993; 37 (4): 255-263).
De Santes et al. (Cancer Res. Apr. 1, 1992; 52: 1916-1923).
Kipps et al. (J. Exp. Med. Jan. 1, 1985; 161 (1): 1-17).
Masui et al. (Cancer Res. Nov. 1986; 46 (11): 5592-5598).
Kim et al. (Int. J. Cancer. 2002; 102: 428-434).
Vuist et al. (Cancer Res. Sep. 15, 1990; 50 (18): 5767-5772).
Campbell et al (Blood Reviews, 17:143-152, 2003.
Bergers, Gabriele et al., “Extrinsic regulators of epithelial tumor progression: metalloproteinases,”Current Opinion in Genetics&Development, vol. 10:120-127 (2000).
Bodey, Bela et al., “Failure of Cancer Vaccines: The Significant Limitations of this Approach to Immunotherapy,”Anticancer Research, vol. 20:2665-2676 (2000).
Fernandes, Dancella M. et al., “A Monoclonal Antibody Reactive with a 40-kDa Molecule on Fetal Thymocytes and Tumor Cells Blocks Proliferation and Stimulates Aggregation and Apoptosis,”The Journal of Immunology, vol. 163:1306-1314 (1999).
Gura, Trisha, “Systems for Identifying New Drugs Are Often Faulty,”Science, vol. 278(5340):1041-1042 (1997).
Hellström, Ingegerd et al., “Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside,”Proc. Natl. Acad. Sci. USA, vol. 82:1499-1502 (1985).
Kasai, Masataka et al., “A New Differentiation Antigen (FT-1) Shared with Fetal Thymocytes and Leukemic Cells in the Mouse,”J. Exp. Med., vol. 159:971-980 (1983).
Lewis, Gail D. et al., “Growth Regulation of Human Breast and Ovarian Tumor Cells by Heregulin: Evidence for the Requirement of ErbB2 as a Critical Component in Mediating Heregulin Responsiveness,”Cancer Research, vol. 56:1457-1465 (1996).
Malard, Veronique et al., “21.1.1, A Novel Activation Marker of T and B Cells,”Molecular Immunology, vol. 28(4/5):417-426 (1991).
Mountain, A. et al., “Engineering Antibodies for Therapy,”Biotechnology&Genetic Engineering Reviews, vol. 10, Michael P. Tombs Ed., pp. 1-143 (1992).
O'Boyle, Kevin P. et al., “Patterns of Ganglioside Expression in B Cell Neoplasms,”Leukemia and Lymphoma, vol. 21:255-266 (1996).
Pinto, Valerian B. et al., “Characterization of the Proliferative Response of CD4-8-Thymic T Lymphoma Cell Line to Stimulation by Thymic Cellular Elements,”The Journal of Immunology, vol. 147:42-49 (1991).
Reichert, Roger A. et al., “Ontogeny of Lymphocyte Homing Receptor Expression in the Mouse Thymus,”The Journal of Immunology, vol. 136(10):3535-3542 (1986).
Retter, Marc W. et al., “Characterization of a Proapoptotic Antiganglioside GM2 Monoclonal Antibody and Evaluation of its Therapeutic Effect on Melanoma and Small Cell Lung Carcinoma Xenografts,”Cancer Research, vol. 65:6425-6434 (2005).
Saito, Masaki et al., “Distinctive Characteristics of Ganglioside-Profiles in Human Leukemia-Lymphoma Cell Lines,”New Vistas in Glycolipid Research, Akira Makita ed., Plenum Press, pp. 369-391 (1982).
Stancovski, Ilana et al., “Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth,”Proc. Natl. Acad. Sci. USA, vol. 88:8691-8695 (1991).
Stobel, Thomas et al., “β1-Integrins Partly Mediate Binding of Ovarian Cancer Cells to Peritoneal Mesothelium in Vitro,”Gynecologic Oncology, vol. 73:362-367 (1999).
Takashi, Tohru et al., “FT-2 Antigen for Distinguishing Lymphocyte Subpopulations in the Developing Thymus,”Immunology Letters, vol. 9:259-262 (1985).
Takei, Fumio, “A Novel Differentiation Antigen on Proliferating Murine Thymocytes Identified by a Rat Monoclonal Antibody,”The Journal of Immunology, vol. 132(2):766-771 (1984).
Tockman, Melvyn S. et al., “Considerations in Bringing a Cancer Biomarker to Clinical Application,”Cancer Research, vol. 52(Suppl.):2711s-2718s (1992).
Vitetta, Ellen S. et al., “Monoclonal Antibodies as Agonists: An Expanded Role for Their Use in Cancer Therapy,”Cancer Research, vol. 54:5301-5309 (1994).
Warren, Andrew P. et al., “CD98: A Type II Transmembrane Glycoprotein Expressed From the Beginning of Primitive and Definitive Hematopoiesis May Play a Critical Role in the Development of Hematopoietic Cells,”Blood, vol. 87(9):3676-3687 (1996).
Yamaguchi, Hiroshi et al., “Human monoclonal antibody with dual GM2/GD2 specificity derived from an immunized melanoma patient,”Proc. Natl. Acad. Sci. USA, vol. 87:3333-3337 (1990).
Zhang, Shengle et al., “Selection of Tumor Antigens as Targets for Immune Attack Using Immunohistochemistry: I. Focus on Gangliosides,”Int. J. Cancer, vol. 73:42-49 (1997).
Caldas, Cristina et al., “Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen,”Molecular Immunology, vol. 39:941-952 (2003).
Chien, Nadine C. et al., “Significant structural and functional change of an antigen-binding site by a distant amino acid sibstitution: Proposal of a structural mechanism,”Proc. Natl. Acad. Sci. USA, vol. 86:5532-5536 (1989).
Giusti, Angela M. et al., “Somatic diversification of S107 from an antiphosphocholine to an anti-DNA autoantibody is due to a single base change in its heavy chain variable region,”Proc. Natl. Acad. Sci. USA, vol. 84:2926-2930 (1987).
Greenspan, Neil S. et al., “Defining epitopes: It's not as easy as it seems,”Nature Biotechnology, vol. 17:936-937 (1999).
Güssow, Detlef et al., “Humanization of monoclonal antibodies,”Methods in Enzymology, vol. 203:99-121 (1991).
Jiang, Beihai et al., “A Novel Peptide Isolated from a Phage Display Peptide Library with Trastuzumab Can Mimic Antigen Epitope of HER-2,”The Journal of Biological Chemistry, vol. 280(6):4656-4662 (2005).
Mariuzza, R.A. et al., “The Structural Basis of Antigen-Antibody Recognition,”Ann. Rev. Biophys. Biophys. Chem., vol. 16:139-159 (1987).
Casset, Florence et al., “A peptide mimetic of an anti-CD4 monoclonal antibody by rational design,”Biochemical and Biophysical Research Communications, vol. 307:198-205 (2003).
Chen, Yvonne et al., “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen,”J. Mol. Biol., vol. 293:865-881 (1999).
De Pascalis, Roberto et al., “Grafting of “Abbreviated” Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody,”The Journal of Immunology, vol. 169:3076-3084 (2002).
Holm, Patrik et al., “Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1,”Molecular Immunology, vol. 44:1075-1084 (2007).
MacCallum, Robert

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Antitumor antibodies, proteins, and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antitumor antibodies, proteins, and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antitumor antibodies, proteins, and uses thereof will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2715452

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.